NervGen Pharma Debt
NGEN Stock | CAD 3.00 0.13 4.15% |
Net Debt To EBITDA is likely to climb to 1.07 in 2024, despite the fact that Net Debt is likely to grow to (19 M). . NervGen Pharma's financial risk is the risk to NervGen Pharma stockholders that is caused by an increase in debt.
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
Given that NervGen Pharma's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which NervGen Pharma is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of NervGen Pharma to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, NervGen Pharma is said to be less leveraged. If creditors hold a majority of NervGen Pharma's assets, the Company is said to be highly leveraged.
At this time, NervGen Pharma's Total Current Liabilities is fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to climb to about 28.8 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 68.7 K in 2024. NervGen |
NervGen Pharma Corp Debt to Cash Allocation
Many companies such as NervGen Pharma, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
NervGen Pharma Corp has accumulated 15.25 M in total debt. NervGen Pharma Corp has a current ratio of 25.21, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist NervGen Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, NervGen Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like NervGen Pharma Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for NervGen to invest in growth at high rates of return. When we think about NervGen Pharma's use of debt, we should always consider it together with cash and equity.NervGen Pharma Total Assets Over Time
NervGen Pharma Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the NervGen Pharma's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of NervGen Pharma, which in turn will lower the firm's financial flexibility.NervGen Pharma Corporate Bonds Issued
NervGen Net Debt
Understaning NervGen Pharma Use of Financial Leverage
Understanding the structure of NervGen Pharma's debt obligations provides insight if it is worth investing in it. Financial leverage can amplify the potential profits to NervGen Pharma's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its cost of debt.
Last Reported | Projected for Next Year | ||
Net Debt | -20 M | -19 M | |
Short and Long Term Debt Total | 255.1 K | 226.8 K | |
Short Term Debt | 77.6 K | 69 K | |
Net Debt To EBITDA | 0.65 | 1.07 | |
Interest Debt Per Share | 0.01 | 0.01 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NervGen Stock Analysis
When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.